Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Abstract PD-1/PD-L1 blockade therapy is a promising cancer treatment strategy, which has
revolutionized the treatment landscape of malignancies. Over the last decade, PD-1/PD-L1 …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine
and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients …

Two different primary malignancies can arise from the adrenal gland: adrenocortical
carcinoma (ACC) from the adrenal cortex and malignant phaeochromocytoma from the …

PURPOSE Adrenocortical carcinoma (ACC) is a rare aggressive pediatric malignancy with
distinct biology. Its treatment follows the principles developed for adults; pediatric-specific …

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a high rate of mortality
and recurrence. N6-methyladenosine methylation (m6A) is the most common modification to …

Background In this multicenter, single‐arm, multicohort, phase 2 trial, the efficacy of
nivolumab and ipilimumab was evaluated in patients with advanced rare genitourinary …

Almost one decade ago, etoposide, doxorubicin, cisplatin and mitotane (EDP-M) has been
established as first-line systemic therapy of metastatic adrenocortical carcinoma (ACC) …

During the recent years, immune checkpoint-based therapy has proven highly effective in
microsatellite instable (MSI) solid tumors irrespective of organ site. MSI tumors are …

Background Adrenocortical carcinoma (ACC) is a rare endocrine malignancy. Tumor-related
glucocorticoid excess is present in~ 60% of patients and associated with particularly poor …